Sequential boost cohort | Simultaneous integrated boost cohort | |
---|---|---|
Characteristic | Number (%) N = 68 | Number (%) N = 141 |
Sex | ||
Male | 56 (82) | 122 (87) |
Female | 12 (18) | 19 (13) |
Age (Median) | 60 (30–75) | 57 (37–88) |
Initial primary tumor site | ||
Hypopharynx | 2 (3) | 6 (4) |
Larynx | 15 (23) | 30 (21) |
Nasopharynx | 1 (1) | 12 (9) |
Oral Cavity | 1 (1) | 6 (4) |
Oropharynx | 48 (71) | 81 (58) |
Paranasal Sinus | 0 (0) | 2 (1) |
Unknown primary | 1 (1) | 4 (3) |
AJCC stage | ||
Stage II | 2 (3) | 3 (2) |
Stage III | 15 (23) | 37 (26) |
Stage IVA | 44 (64) | 83 (59) |
Stage IVB | 5 (7) | 18 (13) |
Stage IVC | 2 (3) | 0 |
ECOG Performance Status | ||
0 | 20 (30) | 39 (28) |
1 | 39 (57) | 97 (69) |
2 | 9 (13) | 5 (3) |
Smoking Status | ||
Current | 25 (37) | 65 (46) |
Former | 23 (34) | 48 (34) |
Never | 20 (29) | 28 (20) |